Knight Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KHTRF research report →
About the company
Knight Therapeutics Inc. operates as a specialized pharmaceutical enterprise, actively engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of a broad spectrum of pharmaceutical goods, consumer health solutions, and medical devices. Its operational footprint extends across Canada, Latin America, and other global markets.
- CEO
- Samira Sakhia
- IPO
- 2014
- Employees
- 745
- HQ
- Montreal, QC, CA
Price Chart
- Market Cap
- $678.62M
- P/E
- 193.18
- P/S
- 1.91
- P/B
- 1.24
- EV/EBITDA
- 14.34
- Div Yield
- 0.00%
- Gross Margin
- 37.32%
- Op Margin
- 2.70%
- Net Margin
- 1.10%
- ROE
- 0.73%
- ROIC
- 1.07%
- Revenue
- $449.72M · 21.12%
- Net Income
- $-5,369,619 · -223.95%
- EPS
- $-0.05 · -220.85%
- Op Income
- $-2,199,206
- FCF YoY
- 1321.39%
- 52W High
- $7.40
- 52W Low
- $4.07
- 50D MA
- $6.17
- 200D MA
- $4.91
- Beta
- 0.05
- Avg Volume
- 6.83K
Get TickerSpark's AI analysis on KHTRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our KHTRF coverage
Recent articles, reports, and earnings notes.
No research on KHTRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KHTRF report →Similar companies
Peers in the same neighborhood.